Comparison Of Outcome Of Microneedling With Autologous PRP Vs Microneedling With Topical Insulin In Treatment Of Post Acne Atrophic Scars.
NCT ID: NCT06002854
Last Updated: 2023-08-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
50 participants
INTERVENTIONAL
2022-08-01
2023-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Various Procedural Treatment Options for Post-acne Atrophic Scars
NCT06770608
Comparison of Efficacy of Microneedling With Platelet Rich Plasma Vs Microneedling With Topical Insulin in the Treatment of Acne Scars
NCT06978361
Efficacy of Intralesional Injection of Pentoxifylline, Platelet-Rich Plasma, and Combined Pentoxifylline With Platelet-Rich Plasma in Patients With Atrophic Acne Scars
NCT06319768
Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne Scars
NCT05573425
Comparative Real-world Study on Ablative Fractional CO₂ Laser vs PRP With Microneedling for Acne Scar Treatment.
NCT07189923
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GROUP A Microneedling with PRP(platelete rich plasma)
PRP( platelet rich plasma) and Insulin human
Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation
GROUP B Microneedling with topical INSULIN
PRP( platelet rich plasma) and Insulin human
Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PRP( platelet rich plasma) and Insulin human
Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Either gender.
* Age 20-50 years.
Exclusion Criteria
* skin cancers and infection
* photosensitivity like SLE ,XP
* use of RETINOIDS in last 6 months.
20 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jinnah Postgraduate Medical Centre
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nazia Jabeen
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
KHADIJA ASADULLAH, MBBS
Role: PRINCIPAL_INVESTIGATOR
JPMC
FAIZA INAM, FCPS
Role: PRINCIPAL_INVESTIGATOR
JPMC
PARISA SANAWAR, FCPS
Role: PRINCIPAL_INVESTIGATOR
JPMC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
JPMC
Karachi, Sindh, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NO.F.2-81/2022-GENL/252/JPMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.